Health
FDA approves first disease-modifying treatment for Alexander disease
Ionis Pharmaceuticals' Zanvastro becomes the initial approved therapy for the rare, fatal neurological condition in children and adults.
The short version
- The FDA approved Ionis Pharmaceuticals' drug Zanvastro as the first disease-modifying therapy for Alexander disease.
- The treatment is authorized for both pediatric and adult patients diagnosed with the rare and fatal neurological disorder.
- Clinical trial results indicated the drug stabilized walking speed, with indications of potential motor function improvement in young children.
- Long-term efficacy and real-world clinical outcomes following commercial rollout remain to be seen.
Key facts
- The FDA granted approval to Ionis Pharmaceuticals for Zanvastro, establishing the first disease-modifying treatment for Alexander disease.[STAT]
- Zanvastro is approved for use in both pediatric and adult patient populations.[STAT]
- In a pivotal clinical trial, patients treated with Zanvastro maintained stable walking speeds, whereas participants in the control group experienced a 33% decline.[STAT]
- Trial researchers reported that the therapy was generally safe, with serious adverse events occurring at a higher rate in the control group than in the treated group.[STAT]
What remains uncertain
- Whether Zanvastro can actively improve motor function in young children, rather than merely stabilizing it, remains preliminary based on trial signals.[STAT]